Traditional drug discovery methods often struggle to address proteins and enzymes considered "undruggable," limiting therapeutic options for various diseases. Current drug delivery methods lack the precision needed to effectively modulate protein function and biology.

General Proximity is developing next-generation proximity medicines that leverage targeted molecular interactions to control biology and enhance therapeutic efficacy. Their platform utilizes an unbiased effector discovery engine to identify proximity mechanisms for specific targets, enabling the development of highly efficacious therapeutics. By manipulating the proximity of target and effector proteins, General Proximity aims to achieve precise control over protein function, including activation, refolding, relocalization, and degradation. This approach allows for the creation of novel therapeutics for targets previously considered beyond the reach of medicine, addressing limitations in current drug discovery and delivery methods. The company's technology facilitates the development of generalized, mechanism-agnostic proximity-based therapies.

Unbiased effector discovery platform for identifying proximity mechanisms

Targeted molecular interactions to modulate protein function

Ability to control protein activation, refolding, relocalization, and degradation

Development of therapeutics for previously "undruggable" targets

Generalized, mechanism-agnostic proximity discovery engine

General Proximity's primary target audience includes researchers and pharmaceutical companies focused on drug discovery and development, particularly those working on challenging or previously undruggable targets in areas such as longevity, neurodegeneration, and metabolic disease.